Confirming specific etiologies of most epilepsies, even those with well-defined histopathological features, has been challenging. Although hippocampal sclerosis was initially described more than 130 years ago, the cause of neuronal loss and gliosis in most persons with mesial temporal lobe epilepsy (MTLE) remains unknown. Several studies of viruses in hippocampal tissue from epilepsy surgery for MTLE have found human herpes virus (HHV) 6B in a majority of samples. Fotheringham and colleagues from the NINDS reported that 15 of 24 brain specimens from patients with hippocampal sclerosis were polymerase chain reaction (PCR) positive for HHV-6B, compared to 0 of 14 from other syndromes, such as cavernous hemangioma and focal cortical dysplasia (1). Citing prior evidence indicating that MTLE is related to glutamate transporter dysfunction, they infected astrocytes in vitro with HHV-6B and found marked decrease in glutamate transporter EAAT-2 expression. They concluded that the "statistically significant correlation of HHV-6 and MTLE in a large cohort of patients with epilepsy and dysregulation of glutamate transporter expression by HHV-6 suggests a novel pathophysiological mechanism of disease. " In contrast to the compelling findings from the NINDS and other studies (2), investigators from Bonn only found HHV-6B in persons with MTLE and a history of documented encephalitis; 0 of 16 with mesial temporal sclerosis of unknown cause (including six with a history of complex febrile seizures) were positive for HHV-6B (3). None of the cases of encephalitis were known to be due to HHV, and several had documentation of other etiologies. Also, no HHV-6B protein was found in any of the encephalitis cases. They conclude that "the fact that we did not detect HHV-6 in idiopathic MRI or lesion-associated TLE contradicts HHV-6 as an etiologic agent…our present data suggest that HHV-6 DNA accumulates only in a subgroup of tissue samples for pharmacoresistant TLE patients after encephalitis from other causes" (3). Although HHV-6B remains a suspicious potential culprit, the specific etiology for MTLE remains unconfirmed for most patients.
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In another recent study, human papilloma virus (HPV) 16 E6 was identified by PCR in all tissue samples of focal cortical dysplasia (FCD) IIB from 50 patients who had surgery for pharmacoresistant epilepsy; all 34 control samples were negative (4). Wong provided a thoughtful review of this remarkable investigation in a prior issue of Epilepsy Currents, highlighting several unresolved aspects of the evidence for HPV as an etiology for FCD IIB and subsequent epilepsy (5) . Models of cytomegaly and cell proliferation, such as tuberous sclerosis complex (TSC), have implicated loss of inhibition of mTORC1 activity as a cause of tubers and the TSC phenotype Focal cortical dysplasia is a common cortical malformation and an important cause of epilepsy. There is evidence for shared molecular mechanisms underlying cortical dysplasia, ganglioglioma, hemimegalencephaly, and dysembryoplastic neuroepithelial tumor. However, there are no familial reports of typical cortical dysplasia or co-occurrence of cortical dysplasia and related lesions within the same pedigree. We report the clinical, imaging, and histologic features of six pedigrees with familial cortical dysplasia and related lesions. Twelve patients from six pedigrees were ascertained from pediatric and adult epilepsy centers, eleven of whom underwent epilepsy surgery. Pedigree data, clinical information, neuroimaging findings, and histopathologic features are presented. The families comprise brothers with focal cortical dysplasia, a male and his sister with focal cortical dysplasia, a female with focal cortical dysplasia and her brother with hemimegalencephaly, a female with focal cortical dysplasia and her female first cousin with ganglioglioma, a female with focal cortical dysplasia and her male cousin with dysembryoplastic neuroepithelial tumor, and a female and her nephew with focal cortical dysplasia. This series shows that focal cortical dysplasia can be familial and provides clinical evidence suggesting that cortical dysplasia, hemimegalencephaly, ganglioglioma, and dysembryoplastic neuroepithelial tumors may share common genetic determinants. (6) ; HPV 16 E6 appears to activate mTOR signaling (7) , which provides a possible mechanism for the cytomegalic pathological findings in both FCD IIB and cervical cancer. However, the transfection of HPV 16 E6 into fetal mouse brains caused focal cortical malformation in association with enhanced mTORC1 signaling but not cytomegaly (4) . Although nearly all cervical cancer is associated with a HPV, only 50% is due to 16 E6 (8) , which begs the question of why the 100% association of FCD IIB with HPV 16 E6? Does 16 E6 penetrate the blood-brain barrier better than other strains of HPV in early brain development, or does 16 E6 contribute to a specific somatic mutation or epigenetic effect that result in FCD IIB? What causes the recurrent seizures and pharmacoresistance commonly seen in patients with cortical dysplasia? Many aspects of the pathophysiology of FCD IIB and its mechanistic relationship with pharmacoresistant epilepsy remain unresolved.
Familial or Infectious…or Both? The Complexity of Confirming Causality of Cortical Malformations
Although the correlation of FCD IIB with HPV appears strong, this association does not exclude the possibility of genetic susceptibility. Leventer and colleagues recently presented the pedigrees of six families with two members each that had FCD, ganglioglioma, hemimegalencephaly, or dysembrioplastic neuroepithelial tumor (DNET) (9) . Eleven of the 12 patients in the study had histopathological diagnosis from surgical specimens. Interestingly, the probands from three of the families had FCD IIB. The other affected members from these three families had either DNET (cousin), FCD (nephew), or FCD plus hippocampal sclerosis (sister). None of the tissue specimens were tested for HPV. Some authors have suggested that developmental tumors (such as DNET and ganglioglioma) result from mTOR signaling abnormalities, which could implicate any cause of mTOR dysregulation (e.g., HPV) as a potential etiology (10) . These "mTORopathies" may constitute a spectrum of cytomegalic malformations that include FCD IIB and ganglioglioma, for which HPV 16 E6 could be a plausible etiology. However, Crino and colleagues found that tissue from 0 of 5 specimens of ganglioglioma were positive for HPV, suggesting that HPV 16 E6 is a specific etiological factor for FCD IIB (4). It seems unlikely that the multiple occurrences of developmental malformations in the families studied by Leventer et al. were spurious; however, prenatal exposures to HPV 16 E6 would not account for all of the identified malformations (i.e., ganglioglioma). Although FCD IIB appears to have a strong association with HPV 16 E6, the complete etiological story is still unfolding, and may include genetic susceptibility as a factor.
The specific malformation occurring in a person with epilepsy may be the result of environmental exposure and genetic susceptibility, possibly mediated by mTOR dysregulation. Although complex and potentially multifactorial, the causal mechanisms of common epilepsies are becoming progressively better understood through recent innovative advances in neuroscience.
by Frank G. Gilliam, MD, MPH
